Nanoparticles with switchable shells for virus sensing and inhibition

Información del proyecto

rSAMs-NANO

Identificador del acuerdo de subvención: 794999

DOI

10.3030/794999

Proyecto cerrado

Fecha de la firma de la CE 10 Abril 2018

Fecha de inicio 3 Septiembre 2018

Fecha de finalización 2 Septiembre 2020

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total

€ 185 857,20

Aportación de la UE

€ 185 857,20

Coordinado por

MALMO UNIVERSITET
Sweden

Objetivo

This proposal concerns Reversible Self-assembled Monolayers (rSAMs) as dynamic nanoparticle shells for multivalent interactions at biointerfaces. Current drug design and diagnostics are exploring the multivalency concept, i.e. binding of biological targets via multiple weak interactions. In contrast to classical drug design relying on high-affinity inhibitors, this
relies on dendritic architectures featuring a high density of ligands, e.g. saccharides, capable of simultaneously interacting with biointerfacial receptors. This strategy can be used to inhibit the virus entry by blocking the receptor at the early stages of infection and the concept is being explored as antiviral drugs and in virus sensing. However, in current systems ligands are covalently fixed on the particle surface. This prevents control over the ligand distribution and composition which compromises selectivity and affinity of the interactions. rSAMs are pH-switchable versions of thiol-SAMs. They are tunable with respect to the nature of the head group and layer order and stability while featuring pH responsiveness and the dynamic nature of non-covalently build assemblies e.g. lipid bilayers. Ligand decorated rSAMs therefore feature strongly enhanced affinities for multivalent targets.
The main aims of this proposal are:
1) to investigate the use of rSAMs as dynamic nanoparticle shells for multivalent inhibition of viruses and 2) to assess such
systems as nanoplasmonic sensors for antibody-free ultrasensitive, robust and rapid in situ virus detection.
Under 1) we will select model pathogens, e.g. Ebola and prepare a series of saccharide terminated amidines for the first generation dynamic shell nanoparticles.Their efficiency will be assessed in infection assays using artificial virus particles
Under 2) we will develop influenza virus sensors with subtyping capability within human and animal virus strains. The sensors will be validated with respect to benchmark assays.

Ámbito científico (EuroSciVoc)

• ciencias naturales › ciencias biológicas › microbiología › virología
• ciencias médicas y de la salud › medicina básica › química medicinal
• ciencias médicas y de la salud › ciencias de la salud › enfermedad infecciosa › virus de ARN › gripe
• ingeniería y tecnología › nanotecnología › nanomateriales
• ciencias médicas y de la salud › medicina básica › farmacología y farmacia › medicamento › antivírico

Programa(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions PROGRAMA PRINCIPAL
  
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
  

Tema(s)

• MSCA-IF-2017 - Individual Fellowships
  

Régimen de financiación

MSCA-IF-EF-CAR - CAR – Career Restart panel

Convocatoria de propuestas

H2020-MSCA-IF-2017

Coordinador

MALMO UNIVERSITET

• Aportación neta de la UEn: € 185 857,20
• Dirección: NORDENSKIOLDSGATAN 1 ; 205 06 MALMOE ; Suecia
• Región: Södra Sverige › Sydsverige › Skåne län
• Tipo de actividad: Higher or Secondary Education Establishments
• Coste total: € 185 857,20